Myoinositol as a Biomarker in Recurrent Glioblastoma Treated with Bevacizumab: A 1H-Magnetic Resonance Spectroscopy Study

Eike Steidl; Ulrich Pilatus; Elke Hattingen; Joachim P. Steinbach; Friedhelm Zanella; Michael W. Ronellenfitsch; Oliver Bähr

doi:10.1371/journal.pone.0168113

Loading metrics

Open Access

Peer-reviewed

Research Article

Myoinositol as a Biomarker in Recurrent Glioblastoma Treated with Bevacizumab: A ¹H-Magnetic Resonance Spectroscopy Study

Eike Steidl ,

* E-mail: steidl@med.uni-frankfurt.de

Affiliations Dr. Senckenberg Institute of Neurooncology, Center for Neurology and Neurosurgery, Johann Wolfgang Goethe-University, Frankfurt/Main, Germany, Institute of Neuroradiology, Center for Neurology and Neurosurgery, Johann Wolfgang Goethe-University, Frankfurt/Main, Germany, German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, Germany

http://orcid.org/0000-0001-7464-0236

⨯
Ulrich Pilatus,

Affiliation Institute of Neuroradiology, Center for Neurology and Neurosurgery, Johann Wolfgang Goethe-University, Frankfurt/Main, Germany
⨯
Elke Hattingen,

Current address: Neuroradiology, Department of Radiology, University Hospital Bonn, Bonn, Germany

Affiliation Institute of Neuroradiology, Center for Neurology and Neurosurgery, Johann Wolfgang Goethe-University, Frankfurt/Main, Germany
⨯
Joachim P. Steinbach,

Affiliations Dr. Senckenberg Institute of Neurooncology, Center for Neurology and Neurosurgery, Johann Wolfgang Goethe-University, Frankfurt/Main, Germany, German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, Germany
⨯
Friedhelm Zanella,

Affiliation Institute of Neuroradiology, Center for Neurology and Neurosurgery, Johann Wolfgang Goethe-University, Frankfurt/Main, Germany
⨯
Michael W. Ronellenfitsch,

Affiliations Dr. Senckenberg Institute of Neurooncology, Center for Neurology and Neurosurgery, Johann Wolfgang Goethe-University, Frankfurt/Main, Germany, German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, Germany
⨯
Oliver Bähr

Affiliations Dr. Senckenberg Institute of Neurooncology, Center for Neurology and Neurosurgery, Johann Wolfgang Goethe-University, Frankfurt/Main, Germany, German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, Germany
⨯

Myoinositol as a Biomarker in Recurrent Glioblastoma Treated with Bevacizumab: A ¹H-Magnetic Resonance Spectroscopy Study

Eike Steidl,
Ulrich Pilatus,
Elke Hattingen,
Joachim P. Steinbach,
Friedhelm Zanella,
Michael W. Ronellenfitsch,
Oliver Bähr

Published: December 29, 2016
https://doi.org/10.1371/journal.pone.0168113

Reader Comments (0)

Post a new comment on this article

Subject Areas
?

For more information about PLOS Subject Areas, click here.
We want your feedback. Do these Subject Areas make sense for this article? Click the target next to the incorrect Subject Area and let us know. Thanks for your help!

Cancers and neoplasms
Is the Subject Area "Cancers and neoplasms" applicable to this article?

Thanks for your feedback.
Cancer treatment
Is the Subject Area "Cancer treatment" applicable to this article?

Thanks for your feedback.
Glioblastoma multiforme
Is the Subject Area "Glioblastoma multiforme" applicable to this article?

Thanks for your feedback.
Metabolites
Is the Subject Area "Metabolites" applicable to this article?

Thanks for your feedback.
Edema
Is the Subject Area "Edema" applicable to this article?

Thanks for your feedback.
Magnetic resonance imaging
Is the Subject Area "Magnetic resonance imaging" applicable to this article?

Thanks for your feedback.
Magnetic resonance spectroscopy
Is the Subject Area "Magnetic resonance spectroscopy" applicable to this article?

Thanks for your feedback.
Survival analysis
Is the Subject Area "Survival analysis" applicable to this article?

Thanks for your feedback.